 |
GUANGZHOU, China, March 28, 2025 /PRNewswire/ — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in Internet healthcare solutions, has been named to the 2024 Guangzhou Artificial Intelligence Innovation Development List as “Most Promising Enterprise,” while its H2H Smart Healthcare Ecosystem secured a spot on the “Application Scenario Innovation List” as a Top 10 AI+Healthcare Case. The awards, issued by the Guangzhou Municipal Science and Technology Bureau, highlight Fangzhou’s groundbreaking innovations in technology and its leadership in transforming the digital healthcare industry.
Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, “Being recognized among Guangzhou’s top AI innovators reflects Fangzhou’s success in developing practical and scalable AI solutions for healthcare. This achievement reinforces our commitment to advancing an intelligent healthcare ecosystem that improves efficiency and accessibility.”
Strategic AI Collaboration with Tencent
Fangzhou has deepened its collaboration with Tencent Health and Tencent Cloud to accelerate AI-driven healthcare solutions, integrating the open-source DeepSeek-V3 and DeepSeek-R1 models into its platform. Following the local deployment of DeepSeek’s large language model in February, the partnership leverages Tencent’s cloud infrastructure to power Fangzhou’s upgraded “AI Agent 2.0” platform, targeting transformative applications in pharmaceutical logistics and healthcare services.
Flagship AI Modules for Enhanced Efficiency
The Company’s “AI + H2H Smart Healthcare Ecosystem” features four core AI modules: AI Physician Assistant, AI Customer Engagement Assistant, AI Procurement Orchestrator, and AI Content Assistant. These tools are designed to streamline operations — from diagnostics to supply chain management — while improving patient and customer experiences across the platform.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is China’s leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com.
About the “Guangzhou Artificial Intelligence Innovation Development List”
Now in its third consecutive year, the “Guangzhou AI Innovation Development List” recognizes the city’s most impactful and promising artificial intelligence enterprises. By highlighting these industry leaders and their cutting-edge applications, the initiative strengthens collaboration across Guangzhou’s AI value chain and fosters a more connected ecosystem.
Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements